

# Cystic Fibrosis - Pipeline Review, H1 2020

<https://marketpublishers.com/r/CC268F2729CEN.html>

Date: April 2020

Pages: 502

Price: US\$ 2,000.00 (Single User License)

ID: CC268F2729CEN

## Abstracts

Cystic Fibrosis - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H1 2020, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body's organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued

projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 34, 20, 1, 67, 32 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based

on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Cystic Fibrosis - Overview

Cystic Fibrosis - Therapeutics Development

Cystic Fibrosis - Therapeutics Assessment

Cystic Fibrosis - Companies Involved in Therapeutics Development

Cystic Fibrosis - Drug Profiles

Cystic Fibrosis - Dormant Projects

Cystic Fibrosis - Discontinued Products

Cystic Fibrosis - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Cystic Fibrosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Cystic Fibrosis - Pipeline by 4D Molecular Therapeutics Inc, H1 2020

Cystic Fibrosis - Pipeline by AbbVie Inc, H1 2020

Cystic Fibrosis - Pipeline by Abeona Therapeutics Inc, H1 2020

Cystic Fibrosis - Pipeline by Agile Sciences Inc, H1 2020

Cystic Fibrosis - Pipeline by AGILeBiotics BV, H1 2020

Cystic Fibrosis - Pipeline by Airway Therapeutics LLC, H1 2020

Cystic Fibrosis - Dormant Projects, H1 2020

Cystic Fibrosis - Discontinued Products, H1 2020

Cystic Fibrosis - Discontinued Products, H1 2020 (Contd..1), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Cystic Fibrosis, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

4D Molecular Therapeutics Inc  
AbbVie Inc  
Abeona Therapeutics Inc  
Agile Sciences Inc  
AGILeBiotics BV  
Airway Therapeutics LLC  
Alaxia SAS  
AlgiPharma AS  
Altavant Sciences Inc  
Amgen Inc  
Antabio SAS  
Arch Biopartners Inc  
Arcturus Therapeutics Ltd  
Armata Pharmaceuticals Inc  
Arrebus Inc  
Arrowhead Pharmaceuticals Inc  
AstraZeneca Plc  
Atlantic Healthcare Plc  
Avidin Ltd  
BioAegis Therapeutics Inc  
Biofilm Pharma

Biolytx Pharmaceuticals Corp  
Boehringer Ingelheim International GmbH  
Boston Pharmaceuticals Inc  
Breathe Easy Therapeutics Ltd  
BridgeBio Pharma Inc  
Calista Therapeutics Inc  
Calithera Biosciences Inc  
Catabasis Pharmaceuticals Inc  
Celtaxsys Inc  
Chiesi Farmaceutici SpA  
Chrysalis Pharma SAS  
Cilian AG  
Copernicus Therapeutics Inc  
Corbus Pharmaceuticals Inc  
CRISPR Therapeutics AG  
CrowdOut Therapeutics  
CSA Biotechnologies LLC  
Cyclacel Pharmaceuticals Inc  
Cyclenium Pharma Inc  
Daiichi Sankyo Co Ltd  
Destiny Pharma Plc  
DiscoveryBiomed Inc  
Druggability Technologies Holdings Ltd  
Editas Medicine Inc  
Eloxx Pharmaceuticals Inc  
EmphyCorp Inc  
EnBiotix Inc  
Enterprise Therapeutics Ltd  
Entrinsic Health Solutions, Inc.  
Enzyvant Sciences Ltd  
Errant Gene Therapeutics LLC  
Evaxion Biotech ApS  
Evotec SE  
Exotect LLC  
Galapagos NV  
Galenus Therapeutics Inc  
Generation Bio Corp  
Genzyme Corp  
Grupo Praxis Pharmaceutical SA



Helperby Therapeutics Group Ltd  
Horizon Therapeutics PLC  
Icagen Inc  
Idorsia Pharmaceutical Ltd  
Immun System IMS AB  
Insmmed Inc  
Invion Ltd  
Ionis Pharmaceuticals Inc  
Kamada Ltd  
Kither Biotech Srl  
Kyorin Pharmaceutical Co Ltd  
Lakewood-Amedex Inc  
Lamellar Biomedical Ltd  
Laurent Pharmaceuticals Inc  
MannKind Corp  
Mariposa Health Ltd  
Microbion Corp  
Mucokinetica Ltd  
Nanogenics Ltd  
Neupharma Srl  
New Amsterdam Sciences Inc  
Novabiotics Ltd  
Novartis AG  
Novoteris LLC  
Omnispirant Ltd  
Orphomed Inc  
OrPro Therapeutics Inc  
Oryn Therapeutics  
Paranta Biosciences Ltd  
Parion Sciences Inc  
Pharmaero ApS  
Pharmaxis Ltd  
PhaseBio Pharmaceuticals Inc  
Polyphor AG  
Progenra Inc  
ProQR Therapeutics NV  
Protalix BioTherapeutics Inc  
Proteostasis Therapeutics Inc  
Pulmatrix Inc

Rare Partners Srl  
Recode Therapeutics Inc  
Renovion Inc  
Riptide Bioscience Inc  
Santhera Pharmaceuticals Holding AG  
SciBac Inc  
Sequoia Sciences Inc  
Silurian Pharmaceuticals Inc  
SolAeroMed Inc  
Specific Biologics Inc  
Spirovant Sciences Inc  
Spyryx Biosciences Inc  
Synedgen Inc  
Synovo GmbH  
Synspira LLC  
Takeda Pharmaceutical Co Ltd  
TGV-Inhalonix Inc  
Therapeutic Systems Research Laboratories Inc  
Translate Bio Inc  
TruCode Gene Repair Inc  
Vast Therapeutics Inc  
Vectura Group Plc  
Verona Pharma Plc  
Vertex Pharmaceuticals Inc  
Vironika LLC  
Zambon Co SpA  
Zata Pharmaceuticals Inc  
Zikani Therapeutics Inc

## I would like to order

Product name: Cystic Fibrosis - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/CC268F2729CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC268F2729CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970